Create an Account - Increase your productivity, customize your experience, and engage in information you care about.
Since April 2021, cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna). The Centers for Disease Control and Prevention (CDC) is aware of these reports, which are rare given the number of vaccine doses administered.
CDC ACIP’s vaccine safety monitoring workgroup (VaST) reviewed data on this a week ago, concluding that “there are relatively few reports of myocarditis to date and that these cases seem to occur:
Most cases are reported to have been mild and quickly responsive to standard management.
Within CDC safety monitoring systems, rates of myocarditis reports in the window following COVID-19 vaccination have not differed from expected baseline rates. However, VaST members felt that information about reports of myocarditis should be communicated to providers.
There is no intention to pause or modify vaccine recommendations based on the current information available. CDC continues to recommend COVID-19 vaccination for everyone 12 years of age and older, given the greater risk of COVID-19 illness and related, possibly severe complications.
The CDC has published Clinical Considerations for myocarditis and pericarditis following COVID-19 vaccination. Additionally, resources for the public have been added to CDC’s website that can be a resource for your patients. The Washington State Department of Health and CDC are actively monitoring these reports, reviewing data and medical records, and working to determine the strength of the association and extent of the phenomenon.